| Clinical data | |
|---|---|
| Other names | EPI-002 |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C21H27ClO5 |
| Molar mass | 394.89 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ralaniten (developmental code nameEPI-002) is anN-terminal domain antiandrogen which was never marketed.[1] It is aderivative ofbisphenol A[2] and one of the fourstereoisomers ofEPI-001.[1] Aprodrug of ralaniten,ralaniten acetate (EPI-506), was under development for the treatment ofprostate cancer.[3]
Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |